QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

• ClinicalTrials.gov Identifier: NCT03563157
• Recruitment Status: Active, not recruiting
• First Posted: June 20, 2018
• Last Update Posted: September 18, 2020
• Sponsor: NantKwest, Inc.
• Information provided by (Responsible Party): NantKwest, Inc.

Study Description

Brief Summary:

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib in Subjects with CRC Who have Previously Treated with SOC.

Condition or disease	Intervention/treatment	Phase
Colorectal Cancer Metastatic; mCRC	Biological: Aldoxorubicin Hydrochloride; Biological: ALT-803; Biological: ETBX-011; Biological: ETBX-021; Biological: ETBX-051; Biological: ETBX-061; Biological: GI-4000; Biological: GI-6207; Biological: GI-6301; Biological: haNK; Drug: Avelumab; Drug: Capecitabine; Drug: Cetuximab; Drug: Cyclophosphamide; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Nab-paclitaxel; Drug: Oxaliplatin; Drug: Regorafenib; Procedure: SBRT	Phase 1; Phase 2

Detailed Description:

NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with Standard-Of-Care Therapy

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 332 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
• Actual Study Start Date: May 25, 2018
• Estimated Primary Completion Date: December 30, 2021
• Estimated Study Completion Date: December 30, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: NANT Colorectal Cancer (CRC) Vaccine; A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.	Biological: Aldoxorubicin Hydrochloride; Aldoxorubicin Hydrochloride HCI; Biological: ALT-803; Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]; Biological: ETBX-011; Ad5 [E1-, E2b-]-CEA; Biological: ETBX-021; Ad5 [E1-, E2b-]-[HER2]; Biological: ETBX-051; Ad5 [E1-, E2b-]-Brachyury; Biological: ETBX-061; Ad5 [E1-, E2b-]-mucin 1 [MUC1]; Biological: GI-4000; RAS yeast; Biological: GI-6207; CEA yeast; Biological: GI-6301; Brachyury yeast; Biological: haNK; haNK™, NK-92 [CD16.158V, ER IL-2]; Drug: Avelumab; BAVENCIO® injection; Drug: Capecitabine; XELODA® tablets; Drug: Cetuximab; ERBITUX® injection; Drug: Cyclophosphamide; Cyclophosphamide Capsules; Drug: 5-Fluorouracil; 5-FU; Fluorouracil Injection; Drug: Leucovorin; Leucovorin Calcium; Drug: Nab-paclitaxel; ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]; Drug: Oxaliplatin; ELOXATIN® injection; Drug: Regorafenib; STIVARGA® tablets; Procedure: SBRT; Stereotactic body radiation therapy
Active Comparator: Regorafenib; In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.	Drug: Regorafenib; STIVARGA® tablets

Outcome Measures

Primary Outcome Measures :

1. Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03 [ Time Frame: 2 years ]
   Phase 1b
2. Progression Free Survival from baseline to progression, per RECIST 1.1 [ Time Frame: 2 years ]
   Phase 2 Randomized Component
3. Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1 [ Time Frame: 1 year ]
   Phase 2 Single Arm Component

Secondary Outcome Measures :

1. ORR for Phase 1b and Phase 2 Randomized Component [ Time Frame: 1 year ]
   Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC
2. PFS for Phase 1b and Phase 2 Single Arm Component [ Time Frame: 2 years ]
   Progression Free Survival from baseline to progression per RECIST 1.1 and irRC
3. OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
   Overall Survival from first treatment to date of death (any cause)
4. DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
   Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC
5. DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 1 year ]
   Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC
6. QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component [ Time Frame: 2 years ]
   Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥ 18 years.
2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines.
3. Histologically-confirmed recurrent or metastatic CRC previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy; or subjects who are ineligible for these therapies.
4. ECOG performance status of 0 or 1.
5. Have at least 1 measurable lesion of ≥ 1.0 cm.
6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
7. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.
8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.

10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, and abstinence.

    Phase 2 single-arm component only

11. Must have progressed on or after regorafenib treatment in the randomized phase 2 portion of the study OR progressed or experienced unacceptable toxicity on SoC and regorafenib prior to enrollment on the study.

Exclusion Criteria:

1. MSI-high or MMR-deficient tumors eligible for, but not yet treated with, a PD-1 inhibitor.
2. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drugs used in this study or that would put the subject at high risk for treatment-related complications.
3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma).
4. History of organ transplant requiring immunosuppression.
5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

6. Inadequate organ function, evidenced by the following laboratory results:

   1. ANC < 1,000 cells/mm^3.
   2. Uncorrectable grade 3 anemia (hemoglobin < 8 g/dL)
   3. Platelet count < 75,000 cells/mm^3.
   4. Total bilirubin > ULN (unless the subject has documented Gilbert's syndrome).
   5. AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
   6. ALP > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
   7. Serum creatinine > 2.0 mg/dL or 177 μmol/L.
   8. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3.
7. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
8. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the institution's lower limit of predicted normal.
9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
10. Positive results of screening test for HIV.
11. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
12. Known hypersensitivity to any component of the study medication(s).
13. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
14. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
15. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
16. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
17. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
18. Concurrent participation in any interventional clinical trial.

19. Pregnant and nursing women.

    Phase 2 randomized component only

20. Prior regorafenib treatment.

Contacts and Locations

Locations

United States, California

Chan Soon-Shiong Institute for Medicine

El Segundo, California, United States, 90245

Sponsors and Collaborators

NantKwest, Inc.

More Information

• Responsible Party: NantKwest, Inc.
• ClinicalTrials.gov Identifier: NCT03563157
• Other Study ID Numbers: QUILT-3.071
• First Posted: June 20, 2018
• Last Update Posted: September 18, 2020
• Last Verified: September 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NantKwest, Inc.:

Colorectal Cancer; Metastatic Colorectal Cancer

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Leucovorin; Paclitaxel; Cyclophosphamide; Fluorouracil; Capecitabine; Oxaliplatin; Cetuximab; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents